Join the CLL Society Inc. on June 3rd for their webinar 'Treatment for CLL: When is the Right Time to Start?'. Learn more and register here: cllsociety.org/2024/05/treatm… #leusm #CLLsm

Wonderful news for our CLL pts! #cllsm

Dr. Furman making sense of ibrutinib discontinuation in #CLLsm during #GDUHEM . ⁦Great Debates & Updates⁩

Big change to NCCN guidelines which now include pirtobrutinib for double exposed CLL pts - hopefully this helps with insurance coverage for pts who aren’t able to do clinical trials #cllsm

Listen to what Dr. Tetiana Skrypets, Haematologist has to say when it comes to having a conversation with patients, who may be experiencing anxiety or depression.

visit: worldlymphomaawarenessday.org to learn more

#WLAD2023 #lymsm #CLLsm

Great start to the morning for the #MDEducation CLL/Lymphoma meeting! #cllsm Matthew Davids, MD, MMSc Adam Kittai

We're so pleased to share our new interactive CLL case study ft. Sanam Loghavi & Matthew Davids, who explore disease diagnosis, prognostication & the importance of genetic testing in CLL.

Discover more below:

👉 ow.ly/F8Zh50RkXjc

#CLLsm #LeuSM

I see your AML talk and raise you a CLL talk - “see” you Saturday! #cllsm

Richter’s Transformation is such a terrible complication of CLL and unmet need. Thankfully we know much more now about the underlying biology. Dr. Erin Parry reviewing the newest findings at #iwCLL23 #iwCLL2023 #CLLsm

Dr. Jennifer Woyach of The James discusses 30m follow-up & subgroup analysis from phase I/II BRUIN study (pirtobrutinib); of 282 pts w/ prior cBTKi, 128 had prior BCL2i (154 BCL2i naive). Similar ORR w/ or w/o prior BCL2i but shorter apparent PFS. #cllsm #ASH23

Outstanding talk on #CLLsm by the disease Guru dr John Byrd at #NEHEME

📣HemaSphere's March issue is now online. Please enjoy reading & sharing (all #OpenAccess ) with your networks 👉hsphere.pub/new_issue.

#LiveSeq #RedCells #Iron #SickleCellDisease #MyeloidMalignancies #hematopoiesis #CLLsm #MMsm #LymphoidMalignancies #CellTherapy #lymsm

👓Review the clinical efficacy of primary BNT162b2 mRNA COVID-19 vaccination in pts with CLL in a real-world setting. Results indicate primary vaccination is significantly assoc with ⬇️risk of SARS-CoV-2 breakthrough infections in pts with CLL 👉bit.ly/3HYA17c
#CLLsm

Great presentation by Dr. Stephens regarding frontline therapy in CLL #cllsm #binaytara

Great times and some of the most amazing Indian food I have ever had courtesy of one of the kindest people and one of the world’s top #CLLsm & #ALLsm experts dr Nitin Jain

👉👉Important analysis from ERIC group in CLL (published in Leukemia)

Time-to-first-Treatment (TTFT) for most somatic mutations is highly dependent on IGHV status

👉TP53ab (mut and/or del17p) with IGHV-M: 10+ yr TTFT !!!

#leusm #CLLsm

nature.com/articles/s4137…

Results of the Global Patient Survey on Lymphoma & CLL help inform advocacy that⬆️patient experience, ⬆️support & care, ⬆️research and ⬆️health policy. Add your voice today. bit.ly/LCGPS2024

#lymphoma #CLL #lymsm #CLL sm

I loved Dr. Parry’s idea of early detection and interception of Richter’s through ctDNA #iwCLL23 #iwCLL2023 #CLLsm

Happening now! Excited for the Q&A session CLL Society Inc. #cllsm

One of the best of #ALLsm & #CLLsm doctors in the world but above all a very kind human Nitin Jain MD Anderson Cancer Center